Buy Jubilant Life Sciences for Target of Rs 496: Daljeet Kohli
Daljeet Kohli, head of research at IndiaNivesh Securities, says Jubilant Life Sciences' pharma business has started to perform and its margins are expected to return to a trajectory of 20-25 per cent in the coming quarters.
